2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
4
Recruiting
2
Withdrawn
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
846
Carcinoma, Non-Small-Cell Lung
553
Neoplasms
516
Prostatic Neoplasms
503
Lung Neoplasms
312
Colorectal Neoplasms
304
Multiple Myeloma
295
Neoplasm Metastasis
255
Melanoma
244
Ovarian Neoplasms
215
Leukemia, Myeloid, Acute
212
Pancreatic Neoplasms
203
Squamous Cell Carcinoma of Head and Neck
171
Carcinoma, Renal Cell
166
Stomach Neoplasms
160
Recurrence
159
Lymphoma
159
Carcinoma, Hepatocellular
159
Glioblastoma
151
Brain Neoplasms
151
Lymphoma, Non-Hodgkin
143
Uterine Cervical Neoplasms
142
Head and Neck Neoplasms
141
Urinary Bladder Neoplasms
137
Leukemia, Lymphocytic, Chronic, B-Cell
137
Triple Negative Breast Neoplasms
136
Precursor Cell Lymphoblastic Leukemia-Lymphoma
132
Hematologic Neoplasms
117
Colonic Neoplasms
117
Lymphoma, Follicular
114
Interventions
vistusertib
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Muscle Invasive Bladder Cancer
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled